What is Brief History of Orchid Pharma Ltd. Company?

Orchid Pharma Ltd. Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

What's the Story Behind Orchid Pharma Ltd.'s Success?

Delve into the fascinating Orchid Pharma Ltd. SWOT Analysis and discover the journey of an Indian pharmaceutical company that has made a significant impact globally. From its humble beginnings as an export-oriented unit, Orchid Pharma has evolved into a major player in drug manufacturing, consistently innovating and expanding its reach. Explore the key milestones and pivotal moments that have shaped Orchid Pharma's trajectory.

This brief history of Orchid Pharma Ltd. will uncover how it became a leading pharmaceutical company. Founded in 1992, Orchid Pharma's journey reflects the dynamic growth of the Indian pharmaceutical industry. Learn about the company's commitment to research and development, its strategic expansions, and how it has navigated the complexities of the global market to establish its current status.

The story of Orchid Pharma Ltd., a prominent pharmaceutical company, began on July 1, 1992. It was established as a 100% Export Oriented Unit (EOU) in Chennai, India. This marked the inception of what would become a significant player in the Indian pharmaceutical industry.

The company's founder, K. Raghavendra Rao, played a crucial role in its early success. Rao, armed with a master's degree in management from the Indian Institute of Management, Ahmedabad, brought a wealth of experience in finance and the pharmaceutical sector. His vision was to leverage India's cost-effective manufacturing capabilities to serve the global market.

Orchid Pharma history is rooted in its initial focus on manufacturing bulk drugs, particularly cephalosporins, for export. Commercial operations started in 1995. Rao's early ventures involved a trip to Oman to raise capital before returning to India in 1993 to set up the company. The company began with a capital of ₹12 crore. Initial sales projections for the first three years were ₹28 crore, ₹32 crore, and ₹37 crore, which they surpassed. Orchid Pharma Ltd became a public company in 1993, a year after its founding. For more details on the company's strategic growth, you can explore the Growth Strategy of Orchid Pharma Ltd.

Key Highlights of Orchid Pharma's Founding

Key milestones and facts about the company's early years.

• Founded: July 1, 1992, as a 100% Export Oriented Unit (EOU).
• Founder: K. Raghavendra Rao, with a background in finance and pharmaceuticals.
• Initial Focus: Manufacturing bulk drugs, especially cephalosporins, for export.
• Capital: Started with ₹12 crore.
• Public Company: Became a public company in 1993.

Orchid Pharma Ltd. SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The early growth of Orchid Pharma Ltd was marked by rapid expansion and strategic initiatives. The Orchid Pharma history began in 1994, setting the stage for significant developments in the Indian pharmaceutical industry. This period saw the company establish itself as a key player in drug manufacturing.

Early Milestones

In 1994, Orchid Pharma initiated operations and entered an agreement with SBD Laboratories Italy for sterile production technology. By 1997, the pharmaceutical company achieved ISO 9002 certification, a testament to its commitment to quality. The company launched its initial product range in 1999, including injectable cephalosporin formulations and co-prescription analgesics.

Product Launch and Market Position

The 1999 product launch included three injectable cephalosporin formulations (Tax-O-bid, Cefogram, Orzid) and two co-prescription analgesics (Orchidol, N-Ltd). Orchid Pharma Ltd quickly became the largest producer of oral and sterile cephalosporin in India. It also ranked among the top five global producers of cephalosporin APIs, showcasing its early market dominance.

Global Expansion and Partnerships

The early 2000s were characterized by significant partnerships and global market entry for Orchid Pharma. The company established offices in the United States and Russia. In 2000, an MoU was signed with Ajanta Pharma Ltd. to acquire their bulk drugs manufacturing plant in Aurangabad.

International Collaborations and Market Reach

International collaborations included partnerships with Par Pharmaceuticals Inc. in 2004 and agreements with Alpharma Inc. and STADA Pharmaceuticals, Inc. in 2005. By 2004, Orchid Pharma Ltd had expanded its global reach to over 70 countries. K. Raghavendra Rao continued to lead as Managing Director during this period.

Orchid Pharma Ltd. PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Mission, Vision & Core Values of Orchid Pharma Ltd. has a rich history marked by significant milestones, including pioneering achievements in the Indian pharmaceutical industry. The company's journey reflects its resilience and adaptability in a competitive market.

A key innovation for Orchid Pharma is the discovery of Enmetazobactam, a New Chemical Entity (NCE), which is the first Indian-discovered drug to receive US FDA approval. This innovation, in combination with Cefepime (ORBLICEF), addresses critical antimicrobial resistance (AMR) concerns.

Enmetazobactam

Enmetazobactam is a significant innovation as the first Indian-discovered drug to gain US FDA approval. This drug, combined with Cefepime, is used to treat complicated infections.

US FDA Approval

The approval of Enmetazobactam by the US FDA highlights the company's research and development capabilities. This approval marked a milestone for the Indian pharmaceutical industry.

Alathur API Facility

The Alathur API facility is India's only USFDA-approved facility for sterile cephalosporins. This facility supports the manufacturing of critical drugs.

Financial difficulties led to a Corporate Debt Restructuring process in 2014-15 and subsequently, the Corporate Insolvency Resolution Process (CIRP) in 2017. During CIRP, the company experienced severe cash crunch and reduced business operations, impacting employee morale.

Financial Restructuring

Orchid Pharma faced financial challenges, leading to a Corporate Debt Restructuring process in 2014-15. The company later underwent the Corporate Insolvency Resolution Process (CIRP) in 2017.

CIRP Impact

During the CIRP, Orchid Pharma experienced a severe cash crunch and reduced business operations. These challenges significantly impacted employee morale and overall business performance.

Acquisition and Turnaround

The acquisition by Dhanuka Laboratories Limited (DLL) on March 31, 2020, marked a significant turning point. Post-acquisition, Orchid Pharma has become profitable and debt-free.

Orchid Pharma Ltd. Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The Orchid Pharma Ltd. is a pharmaceutical company with a history marked by significant milestones. Incorporated in 1992, the company has evolved from an export-oriented unit to a key player in the Indian pharmaceutical industry. Its journey includes achieving ISO 9002 certification early on, expanding its product portfolio, entering into strategic partnerships, and navigating financial challenges. Recent developments indicate a strong focus on growth and innovation, particularly in the area of antimicrobial solutions.

Orchid AMS Division

Orchid Pharma plans to launch its new Orchid AMS division, focusing on marketing novel antibiotics like Enmetazobactam and Cefiderocol to hospitals. The goal is to cover 2,500-3,000 hospitals over the next 2-3 years, expanding its market presence in the pharmaceutical industry.

U.S. Market Growth

The company anticipates further growth in the U.S. market for Enmetazobactam sales, reflecting the company's strategic focus on expanding its presence in key international markets. This expansion is crucial for its financial performance.

Backward Integration

Orchid Pharma is investing ₹6 billion in a new 7-aminocephalosporanic acid (7ACA) manufacturing facility in Jammu. This facility, expected to be operational by the end of FY26, is part of the government's production-linked incentive (PLI) scheme and aims to significantly enhance margins.

R&D and Production Capacity

The company is focused on reviving its R&D strengths and expanding production capacity, aligning with industry trends emphasizing innovation and self-reliance in pharmaceuticals. This will help Orchid Pharma's future growth.

Orchid Pharma Ltd. Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs